PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10708946-4 2000 In our study, we examined the effects of buthionine sulphoximine (BSO), an inhibitor of GSH biosynthesis, on the nuclear accumulation of daunorubicin (DNR), in etoposide (VP16) and doxorubicin (ADR) resistant MCF7 cell lines, overexpressing respectively MRP1 (MCF7/VP) and Pgp (MCF7/ADR). Daunorubicin 137-149 host cell factor C1 Homo sapiens 171-175 2564628-10 1989 In contrast, daunorubicin increased VP-16 accumulation only in the sensitive MCF-7 cell line, whereas the efflux rate of VP-16 was not significantly changed in either cell line. Daunorubicin 13-25 host cell factor C1 Homo sapiens 36-41 7808368-9 1994 In leukemias we administered vincristine (1.5 mg/m2), and daunomycin (40 mg/m2), in solid tumors VP16 (150 mg/m2) and adriamycin (60 mg/m2). Daunorubicin 58-68 host cell factor C1 Homo sapiens 97-101 2539902-1 1989 Our human T-cell leukemia line, CEM/VM-1, selected for resistance to VM-26 (teniposide), is cross-resistant to several drugs that interact with topoisomerase II, including VP-16 (etoposide), 4"-(9-acridinylamino)methanesulphon-m-anisidide, daunorubicin, and mitoxantrone. Daunorubicin 240-252 host cell factor C1 Homo sapiens 172-177 291472-2 1979 In the first patient (a 7-month-old female with acute monocytic leukemia) extremely young age and previous chemotherapy with a podophyllotoxin derivative, VP-16, may have prediposed the patient to fatal congestive heart failure at a total Daunorubicin dose of only 225 mg/m2. Daunorubicin 239-251 host cell factor C1 Homo sapiens 155-160